Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3520 ARTÍCULOS , VIENDO DEL 3166 AL 3180

[123I]FP-CIT (DaTscan) SPECT brain imaging in patients with suspected parkinsonian syndromes

Hauser RA, Grosset DG.

J Neuroimaging. 2012 Jul;22(3):225-30. doi: 10.1111/j.1552-6569.2011.00583.x. Epub 2011 Mar 16.

Parkinson's disease (PD) in the elderly: an example of geriatric syndrome (GS)?

Lauretani F, Maggio M, Silvestrini C, Nardelli A, Saccavini M, Ceda GP.

Arch Gerontol Geriatr. 2012 Jan-Feb;54(1):242-6. doi: 10.1016/j.archger.2011.03.002. Epub 2011 Apr 2.

Regional changes in type 1 cannabinoid receptor availability in Parkinson's disease in vivo

Van Laere K, Casteels C, Lunskens S, Goffin K, Grachev ID, Bormans G, Vandenberghe W.

Neurobiol Aging. 2012 Mar;33(3):620.e1-8. doi: 10.1016/j.neurobiolaging.2011.02.009. Epub 2011 Apr 2.

[Perioperative management of Parkinson's disease]

Mariscal A, Medrano IH, Cánovas AA, Lobo E, Loinaz C, Vela L, Espiga PG, Castrillo JC; Sociedad Española de Neurología.

Neurologia. 2012 Jan;27(1):46-50. doi: 10.1016/j.nrl.2010.12.013. Epub 2011 Apr 5.

The use of echocardiography in Wolff-Parkinson-White syndrome

Cai Q, Shuraih M, Nagueh SF.

Int J Cardiovasc Imaging. 2012 Apr;28(4):725-34. doi: 10.1007/s10554-011-9880-8. Epub 2011 May 1.

Urinary tract dysfunction in Parkinson's disease: a review

Yeo L, Singh R, Gundeti M, Barua JM, Masood J.

Int Urol Nephrol. 2012 Apr;44(2):415-24. doi: 10.1007/s11255-011-9969-y. Epub 2011 May 7.

Toxin models of mitochondrial dysfunction in Parkinson's disease

Martinez TN, Greenamyre JT.

Antioxid Redox Signal. 2012 May 1;16(9):920-34. doi: 10.1089/ars.2011.4033. Epub 2011 Jul 12.

Mitochondrial quality control and dynamics in Parkinson's disease

McCoy MK, Cookson MR.

Antioxid Redox Signal. 2012 May 1;16(9):869-82. doi: 10.1089/ars.2011.4019. Epub 2011 Jul 7.

Ebstein anomaly in an adult presenting with wide QRS tachycardia: diagnostic and therapeutic dilemmas

Rao MP, Panduranga P, Al-Mukhaini M, Al-Jufaili M.

Am J Emerg Med. 2012 Jun;30(5):834.e1-4. doi: 10.1016/j.ajem.2011.03.001. Epub 2011 May 12.

[Levodopa-responsive parkinsonism-dystonia due to a traumatic injury of the substantia nigra]

Pérez Errazquin F, Gomez Heredia MJ.

Neurologia. 2012 Apr;27(3):181-3. doi: 10.1016/j.nrl.2011.03.011. Epub 2011 May 13.

A proof-of-concept, randomized, placebo-controlled, multiple cross-overs (n-of-1) study of naftazone in Parkinson's disease

Rascol O, Ferreira J, Nègre-Pages L, Perez-Lloret S, Lacomblez L, Galitzky M, Lemarié JC, Corvol JC, Brotchie JM, Bossi L.

Fundam Clin Pharmacol. 2012 Aug;26(4):557-64. doi: 10.1111/j.1472-8206.2011.00951.x. Epub 2011 May 18.

Systematic reviews of t'ai chi: an overview

Lee MS, Ernst E.

Br J Sports Med. 2012 Aug;46(10):713-8. doi: 10.1136/bjsm.2010.080622. Epub 2011 May 16.

Recognition by family members that relatives with neurodegenerative disease are likely to die within a year: a meta-ethnography

Hubbard G, McLachlan K, Forbat L, Munday D.

Palliat Med. 2012 Mar;26(2):108-22. doi: 10.1177/0269216311402712. Epub 2011 May 17.

Pharmacokinetics of levodopa/carbidopa delivered from gastric-retentive extended-release formulations in patients with Parkinson's disease

Chen C, Cowles VE, Sweeney M, Stolyarov ID, Illarioshkin SN.

J Clin Pharmacol. 2012 Jul;52(7):1069-77. doi: 10.1177/0091270011409232. Epub 2011 May 24.

Long-term exposure to duodenal levodopa/carbidopa infusion therapy improves quality of life in relation especially to mobility, activities of daily living, and emotional well-being

Santos-García D, Sanjurjo LF, Macías M, Llaneza M, Carpintero P, de la Fuente-Fernández R.

Acta Neurol Scand. 2012 Mar;125(3):187-91. doi: 10.1111/j.1600-0404.2011.01523.x. Epub 2011 May 26.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias